The clinical courses of HBV-related acute-on-chronic liver failure and a multi-state model to predict disease evolution
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases..
BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is a highly dynamic syndrome. The objective of this study was to delineate the clinical course of patients with HBV-ACLF and to develop a model to estimate the temporal evolution of disease severity.
METHODS: We enrolled eligible patients from 2 large, multicenter prospective cohorts. The ACLF grade, organ failures, and outcomes were assessed at multiple time points (days 1/4/7/14/21/28). Probabilities for ACLF transitions between these disease states and to death within 28 days were calculated using a multi-state model that used baseline information and updated ACLF status. The model was validated in independent patients.
RESULTS: Among all the 445 patients with HBV-ACLF, 76 represented disease progression, 195 had a stable or fluctuating course, 8 with improvement, and the remaining 166 with resolution within 28-day follow-up. New coagulation (63.64%) or renal failure (45.45%) was frequently observed during early progression. Patients with disease progression had a higher incidence of new episodes of ascites [10 (13.16%) vs. 22 (5.96%), p = 0.027] and HE [13(17.11%) vs. 21 (5.69%), p = 0.001], and a significant increase in white blood cell count. The multi-state model represented dynamic areas under the receiver operating characteristic curves ranging from 0.71 to 0.84 for predicting all ACLF states and death at 4, 7, 14, 21, and 28 days post-enrollment and from 0.73 to 0.94 for predicting death alone, performing better than traditional prognostic scores.
CONCLUSIONS: HBV-ACLF is a highly dynamic syndrome with reversibility. The multi-state model is a tool to estimate the temporal evolution of disease severity, which may inform clinical decisions on treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Hepatology communications - 8(2024), 1 vom: 01. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Xia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 12.01.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1097/HC9.0000000000000354 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366715755 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366715755 | ||
| 003 | DE-627 | ||
| 005 | 20240114234403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HC9.0000000000000354 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1257.xml |
| 035 | |a (DE-627)NLM366715755 | ||
| 035 | |a (NLM)38180960 | ||
| 035 | |a (PII)e0354 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Xia |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The clinical courses of HBV-related acute-on-chronic liver failure and a multi-state model to predict disease evolution |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 12.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. | ||
| 520 | |a BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is a highly dynamic syndrome. The objective of this study was to delineate the clinical course of patients with HBV-ACLF and to develop a model to estimate the temporal evolution of disease severity | ||
| 520 | |a METHODS: We enrolled eligible patients from 2 large, multicenter prospective cohorts. The ACLF grade, organ failures, and outcomes were assessed at multiple time points (days 1/4/7/14/21/28). Probabilities for ACLF transitions between these disease states and to death within 28 days were calculated using a multi-state model that used baseline information and updated ACLF status. The model was validated in independent patients | ||
| 520 | |a RESULTS: Among all the 445 patients with HBV-ACLF, 76 represented disease progression, 195 had a stable or fluctuating course, 8 with improvement, and the remaining 166 with resolution within 28-day follow-up. New coagulation (63.64%) or renal failure (45.45%) was frequently observed during early progression. Patients with disease progression had a higher incidence of new episodes of ascites [10 (13.16%) vs. 22 (5.96%), p = 0.027] and HE [13(17.11%) vs. 21 (5.69%), p = 0.001], and a significant increase in white blood cell count. The multi-state model represented dynamic areas under the receiver operating characteristic curves ranging from 0.71 to 0.84 for predicting all ACLF states and death at 4, 7, 14, 21, and 28 days post-enrollment and from 0.73 to 0.94 for predicting death alone, performing better than traditional prognostic scores | ||
| 520 | |a CONCLUSIONS: HBV-ACLF is a highly dynamic syndrome with reversibility. The multi-state model is a tool to estimate the temporal evolution of disease severity, which may inform clinical decisions on treatment | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Liu, Xinxin |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Wenting |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jinjun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Beiling |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Zhongji |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yanhang |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Zhiping |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Xiaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Huadong |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yubao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Weituo |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Wenyi |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Guohong |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Xiaomei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Yixin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qun |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Shue |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ruochan |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Liyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xiuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Sen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jinming |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Liujuan |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Rongjiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xinyi |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Haotang |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Jifang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology communications |d 2017 |g 8(2024), 1 vom: 01. Jan. |w (DE-627)NLM273051806 |x 2471-254X |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:1 |g day:01 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HC9.0000000000000354 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 1 |b 01 |c 01 | ||